This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. Additionally, the predictive value of the Khorana score and several other VTE and bleeding prediction scores and risk factors will be evaluated.
Patients with cancer are at high risk of venous thromboembolism (VTE), including deep-vein thrombosis and pulmonary embolism. For cancer patients receiving chemotherapy the incidence of VTE is even higher. Several predictive models were previously developed to identify and justify thromboprophylaxis for cancer patietns who are at highest risk of VTE, like the Khorana and PROTECHT score. The Khorana score is a risk-stratification tool to select patients at high risk of VTE for thromboprophylaxis. The PROTECHT score takes cisplatin-based chemotherapy into account in addition of the Khorana score. Thereby, the incidence of bleeding and VTE in patients with esophageal cancer is not clear. This study aims to assess the 6- and 12-month venous thromboembolism (VTE) and bleeding incidence from the start of cancer diagnosis in a retrospective cohort of patients with esophageal cancer. Additionally, the predictive value of the Khorana score and several other VTE and bleeding prediction scores and risk factors will be evaluated.
Study Type
OBSERVATIONAL
Enrollment
542
Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
Amsterdam UMC
Amsterdam, Netherlands
VTE- and bleeding incidence
6- and 12-month VTE- and bleeding incidence
Time frame: from start of cancer diagnosis
Predictive performance of VTE risk factors and known prediction models
To assess the predictive value of Khorana, modified Vienna-, and PROTECHT score in Predictive performance of VTE risk factors and known prediction models
Time frame: from start cancer diagnosis
Predictive performance of bleeding risk factors and known prediction models
Predictive performance of bleeding risk factors and known prediction models
Time frame: from start cancer diagnosis
Arterial thromboembolism (ATE) incidence
6- and 12-month ATE incidence
Time frame: from start of cancer diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.